These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21631342)

  • 1. Cytarabine dose for acute myeloid leukemia.
    Mori J; Tsubokura M; Kami M
    N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
    [No Abstract]   [Full Text] [Related]  

  • 2. Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
    Wiernik A; Sperr WR; Weisdorf D; Valent P; Ustun C
    Am J Hematol; 2013 Jun; 88(6):533-4. PubMed ID: 23526441
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytarabine dose for acute myeloid leukemia.
    Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
    N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytarabine dose for acute myeloid leukemia.
    Mathisen MS
    N Engl J Med; 2011 Jun; 364(22):2167; author reply 2168-9. PubMed ID: 21631341
    [No Abstract]   [Full Text] [Related]  

  • 5. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.
    Löwenberg B
    Blood; 2013 Jan; 121(1):26-8. PubMed ID: 23287624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated Bilateral Ear and Scalp Rash After Cytarabine Therapy for Acute Myelogenous Leukemia: A Report and Literature Review.
    Waseem H; Henriquez Felipe C; Hashmi AT; Ansar M; Batool A; Saverimuthu A; Kamholz SL
    Am J Ther; 2019; 26(5):e653-e655. PubMed ID: 30418222
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for sinoatrial blockade associated with high dose cytarabine therapy.
    Stamatopoulos K; Kanellopoulou G; Vaiopoulos G; Stamatellos G; Yataganas X
    Leuk Res; 1998 Aug; 22(8):759-61. PubMed ID: 9680105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
    Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
    [No Abstract]   [Full Text] [Related]  

  • 9. Anterior uveitis associated with high-dose cytosine arabinoside.
    Fintelmann RE; Qian Y; Skalet A; Jeng BH
    Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe anterior uveitis as a complication of high-dose cytosine-arabinoside.
    Moberg J; Carlsson M; Holm C; Koranyi G
    Acta Ophthalmol; 2009 Nov; 87(8):922-3. PubMed ID: 19799589
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.
    Sommer C; Lackner H; Benesch M; Sovinz P; Schwinger W; Moser A; Bergloeff J; Gruber A; Urban C
    Ann Hematol; 2008 Nov; 87(11):887-90. PubMed ID: 18575860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Flushing out" cytosine arabinoside from CSF to reverse neurotoxicity.
    Bleyer A
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):274. PubMed ID: 17414574
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
    Horikoshi Y; Kobayashi R; Endo M; Watanabe A; Kikuta A; Koike K; Hanada R; Hosoya R; Ohara A; Ikuta K; Goto H; Asami K; Sugita K; Horibe K; Tsurusawa M; Hori T; Hara J; Nishimura S; Nagatoshi Y; Mugishima H; Ohta S; Adachi S; Tsukimoto I
    Rinsho Ketsueki; 2010 Feb; 51(2):104-13. PubMed ID: 20379101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
    Deisseroth A; Farrell A; Justice R; Kane R; Sridhara R; Chen H; He K; Pazdur R
    Blood; 2010 Jan; 115(2):430. PubMed ID: 20075171
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
    Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
    Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
    [No Abstract]   [Full Text] [Related]  

  • 18. Two cases of cytarabine syndrome successfully resolved by desensitization.
    Lim KH; Kim JY; Kang MG; Park HK; Kang HR
    J Investig Allergol Clin Immunol; 2015; 25(1):80-2. PubMed ID: 25898709
    [No Abstract]   [Full Text] [Related]  

  • 19. Control of acute myeloid leukemia morbidity in northwest Iran.
    Eivazi-Ziaei J
    Asian Pac J Cancer Prev; 2005; 6(4):472-3. PubMed ID: 16435994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
    Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
    Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.